Ann Pediatr Endocrinol Metab.  2021 Jun;26(2):99-104. 10.6065/apem.2040142.071.

Hemostatic state of children with type 1 diabetes

• Aleman MN
• Díaz EI
• Luciardi MC
• Mariani AC
• Bazán MC
• Abregu AV

• KMID: 2517587
• DOI: http://doi.org/10.6065/apem.2040142.071

Abstract

Purpose
Hyperglycemia is one of the factors responsible for the molecular alterations that modify hemostasis. The aim of this study was to determine the levels of circulating molecules that have a prothrombotic impact on the child and adolescent population with type 1 diabetes mellitus.
Methods
There were 35 patients with type 1 diabetes mellitus (11.0±2.5 years of age and a median 3.7±2.0 years of the disease) with no vascular complications and 20 healthy controls with similar age, sex, and body mass index included in the study. The evaluated parameters were fibrinogen, plasminogen activator inhibitor-1 (PAI1), von Willebrand factor antigen, and standard coagulation tests (platelet count, prothrombin time, and activated partial thromboplastin time). Glycemic control was evaluated by hemoglobin A1c and fasting blood glucose tests, and the presence of retinopathy and nephropathy was ruled out. The data obtained were analyzed by IBM SPSS Statistics ver. 20.0 and expressed as mean±standard deviation. The Pearson correlation coefficient was applied to investigate correlations between variables.
Results
Diabetic patients showed significantly higher levels of fibrinogen (308±66 mg/dL vs. 246±18 mg/dL, P=0.0001), PAI-1 (41.6±12 ng/mL vs. 11.7±1.0 ng/mL, P=0.0001), and von Willebrand factor antigen (284%±55% vs. 121%±19%, P=0.0001). However, standard coagulation tests did not show differences between the 2 groups. PAI-1 was correlated with glycemia, hemoglobin A1c, fibrinogen, and von Willebrand factor antigen.
Conclusion
Elevated levels of fibrinogen, PAI-1, and von Willebrand factor antigen were found in the pediatric and adolescent population with type 1 diabetes mellitus, which suggests a prothrombotic state.

Keyword

Type 1 diabetes; Prothrombotic state; Plasminogen activator inhibitor-1; Von Willebrand factor

Figure

• 

  Fig. 1. Scatter plots showing the relationship between the PAI-1 and other variables. PAI-1, plasminogen activator inhibitor-1; vWF:Ag, Von Willebrand Factor:Antigen; FBG, fasting blood glucose; HbA1c, glycosylated hemoglobin A1c. The Pearson correlation coefficient (r) and the P-value are shown at the top of each graph. A P<0.05 was considered significant.

Reference

References

1. Vehik K, Dabelea D. The changing epidemiology of type 1 diabetes: why is it going through the roof? Diabetes Metab Res Rev. 2011; 27:3–13.

2. Targher G, Chonchol M, Zoppini G, Franchini M. Hemostatic disorders in type 1 diabetes mellitus. Semin Thromb Hemost. 2011; 37:58–65.

3. Rodrigues TC, Snell-Bergeon JK, Maahs DM, Kinney GL, Rewers M. Higher fibrinogen levels predict progression of coronary artery calcification in adults with type 1diabetes. Atherosclerosis. 2010; 210:671–3.

4. Alessi MC, Poggi M, Juhan-Vague I. Plasminogen activator inhibitor-1, adipose tissue and insulin resistance. Curr Opin Lipidol. 2007; 18:240–5.

5. Cesari M, Pahor M, Incalzi RA. Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions. Cardiovasc Ther. 2010; 28:72–91.

6. Gragnano F, Sperlongano S, Golia E, Natale F, Bianchi R, Crisci M, et al. The role of von Willebrand Factor in vascular inflammation: from pathogenesis to targeted therapy. Mediators Inflamm. 2017; 2017:5620314.

7. Frankel DS, Meigs JB, Massaro JM, Wilson PW, O'Donnell CJ, D'Agostino RB, et al. Von Willebrand Factor, type 2 diabetes mellitus, and risk of cardiovascular disease: The Framingham Offspring Study. Circulation. 2008; 118:2533–9.

8. Madan R, Gupt B, Saluja S, Kansra UC, Tripathi BK, Guliani BP. Coagulation profile in diabetes and its association with diabetic microvascular complications. J Assoc Physicians India. 2010; 58:481–4.

9. Adly AA, Elbarbary NS, Ismail EA, Hassan SR. Plasminogen activator inhibitor-1 (PAI-1) in children and adolescents with type 1 diabetes mellitus: relation to diabetic microvascular complications and carotid intima media thickness. J Diabetes Complications. 2014; 28:340–7.

10. Carrizo T del R, Prado MM, Velarde MS, Díaz EI, Bazán MC, Abregú AV. Soluble E-Selectin in children and adolescents with type 1 diabetes. Medicina (B Aires). 2008; 68:193–7.

11. Rabago Rodríguez R, Gómez-Díaz RA, Tanus Haj J, Avelar Garnica FJ, Ramirez Soriano E, Nishimura Meguro E, et al. Carotid intima-media thickness in pediatric type 1 diabetic patients. Diabetes Care. 2007; 30:2599–602.

12. Babar GS, Zidan H, Widlansky ME, Das E, Hoffmann RG, Daoud M, et al. Impaired endothelial function in preadolescent children with type 1 diabetes. Diabetes Care. 2011; 34:681–5.

13. American Diabetes Association. 13. Children and adolescents: standards of medical care in diabetes-2020. Diabetes Care. 2020; 43(Suppl 1):S163–82.

14. Romano M, Pomilio M, Vigneri S, Falco A, Chiesa PL, Chiarelli F, et al. Endothelial perturbation in children and adolescents with type 1 diabetes: association with markers of the inflammatory reaction. Diabetes Care. 2001; 24:1674–8.

15. Sobczak A, Stewart AJ. Coagulatory defects in type-1 and type-2 diabetes. Int J Mol Sci. 2019; 20:6345.

16. Carmassi F, Morale M, Puccetti R, De Negri F, Monzani F, Navalesi R, et al. Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus. Thromb Res. 1992; 67:643–54.

17. Binay C, Bozkurt Turhan A, Simsek E, Bor O, Akay OM. Evaluation of coagulation profile in children with type1 diabetes mellitus using rotational thromboelastometry. Indian J Hematol Blood Transfus. 2017; 33:574–80.

18. Blann AD, Lip GY. Endothelial integrity, soluble adhesion molecules and platelet markers in type 1 diabetes mellitus. Diabet Med. 1998; 15:634–42.

19. Sapkota B, Shrestha SK, Poudel S. Association of activated partial thromboplastin time and fibrinogen level in patients with type II diabetes mellitus. BMC Res Notes. 2013; 6:485.

20. Kim HK, Kim JE, Park SH, Kim YI, Nam-Goong IS, Kim ES. High coagulation factor levels and low protein C levels contribute to enhanced thrombin generation in patients with diabetes who do not have macrovascular complications. J Diabetes Complications. 2014; 28:365–9.

21. Targher G, Bertolini L, Zoppini G, Zenari L, Falezza G. Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in type 1 diabetic patients without clinically manifest macroangiopathy. Diabet Med. 2005; 22:999–1004.

22. B ehl T, Velpandian T, Kotwani A. Role of altered coagulation-fibrinolytic system in the pathophysiology of diabetic retinopathy. Vascul Pharmacol. 2017; 92:1–5.

23. Lemkes BA, Hermanides J, Devries JH, Holleman F, Meijers JC, Hoekstra JB. Hyperglycemia: a prothrombotic factor? J Thromb Haemost. 2010; 8:1663–9.

24. Milne R, Brownstein S. Advanced glycation end products and diabetic retinopathy. Amino Acids. 2013; 44:1397–407.

25. Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res. 2010; 106:1319–31.

26. Daniels M, DuBose SN, Maahs DM, Beck RW, Fox LA, Gubitosi-Klug R, et al. Factors associated with microalbuminuria in 7,549 children and adolescents with type 1 diabetes in the T1D Exchange clinic registry. Diabetes Care. 2013; 36:2639–45.

27. Mohammad HA, Farghaly HS, Metwalley KA, Monazea EM, Abd El-Hafeez HA. Predictors of glycemic control in children with Type 1 diabetes mellitus in Assiut-Egypt. Indian J Endocrinol Metab. 2012; 16:796–802.

28. Dutta T, Kudva YC, Persson XM, Schenck LA, Ford GC, Singh RJ, et al. Impact of long-term poor and good glycemic control on metabolomics alterations in type 1 diabetic people. J Clin Endocrinol Metab. 2016; 101:1023–33.

29. Franco MM, Morales MMM, Duarte PM, Napimoga MH, Benatti BB. Glycemic control and the production of cytokines in diabetic patients with chronic periodontal disease. RGO - Revista Gaúcha de Odontologia. 2015; 63:432–8.

30. Kırmızıbekmez H, Güven A, Yıldız M, Dursun F, Cebeci N, Hancili S. Detection of vascular risk markers in children and adolescents with type 1 diabetes. J Pediatr Endocrinol Metab. 2014; 27:87–92.

31. Zhao Y, Zhang J, Zhang J, Wu J. Diabetes mellitus is associated with shortened activated partial thromboplastin time and increased fibrinogen values. PLoS One. 2011; 6:e16470.

32. Sarkisova K, Jarek-Martynowa IR, Shestakova M, Chirkova L, Nikankina L, Shamkhalova M. Effect of HbA1c and hyperglycemia on hemostasis in patients with type 1 diabetes. Endocrine Abstracts. 2019; 63:GP218.

33. Zorio E, Gilabert-Estelles J, Espana F, Ramón LA, Cosín R, Estellés A. Fibrinolysis: the key to new pathogenetic mechanisms. Curr Med Chem. 2008; 15:923–9.

34. Singh NK, Gupta A, Behera DR, Dash D. Elevated plasminogen activator inhibitor type-1 (PAI-1) as contributing factor in pathogenesis of hypercoagulable state in antiphospholipid syndrome. Rheumatol Int. 2013; 33:2331–6.

35. Yarmolinsky J, Bordin Barbieri N, Weinmann T, Ziegelmann PK, Duncan BB, Inês Schmidt M. Plasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis of observational studies. Sci Rep. 2016; 6:17714.